Egr1 Knockdown Combined with an ACE Inhibitor Ameliorates Diabetic Kidney Disease in Mice: Blockade of Compensatory Renin Increase

References

• Wang L, Gao P, Zhang M, et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA. 2017;317:2515. doi:10.1001/jama.2017.7596
   PubMed Web of Science ®Google Scholar
• Xue R, Gui D, Zheng L, Zhai R, Wang F, Wang N. Mechanistic insight and management of diabetic nephropathy: recent progress and future perspective. J Diabetes Res. 2017;2017:1–7. doi:10.1155/2017/1839809
   Web of Science ®Google Scholar
• Yacoub R, Campbell KN. Inhibition of RAS in diabetic nephropathy. Int J Nephrol Renovasc Dis. 2015;8:29–40. doi:10.2147/IJNRD.S37893
   PubMed Web of Science ®Google Scholar
• St PW, Odum LE, Whaley-Connell AT. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease. Pharmacotherapy. 2013;33:496–514. doi:10.1002/phar.1232
   PubMedGoogle Scholar
• Nakamura T, Fujiwara N, Kawagoe Y, Sugaya T, Ueda Y, Koide H. Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease. Eur J Clin Invest. 2010;40:790–796. doi:10.1111/j.1365-2362.2010.02319.x
   PubMed Web of Science ®Google Scholar
• Tan X, He W, Liu Y. Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathy. Kidney Int. 2009;76(12):1248–1257. doi:10.1038/ki.2009.346
   PubMedGoogle Scholar
• Borghi C, Boschi S, Ambrosioni E, Melandri G, Branzi A, Magnani B. Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol. 1993;33:40–45. doi:10.1002/j.1552-4604.1993.tb03901.x
   PubMed Web of Science ®Google Scholar
• Roig E, Perez-Villa F, Morales M, et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J. 2000;21:53–57. doi:10.1053/euhj.1999.1740
   PubMed Web of Science ®Google Scholar
• Sakoda M, Ichihara A, Kaneshiro Y, et al. (Pro)renin receptor-mediated activation of mitogen-activated protein kinases in human vascular smooth muscle cells. Hypertens Res. 2007;30:1139–1146. doi:10.1291/hypres.30.1139
   PubMedGoogle Scholar
• Huang Y, Noble NA, Zhang J, Xu C, Border WA. Renin-stimulated TGF-beta1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. Kidney Int. 2007;72:45–52. doi:10.1038/sj.ki.5002243
   PubMed Web of Science ®Google Scholar
• Wang WN, Zhang WL, Zhou GY, et al. Prediction of the molecular mechanisms and potential therapeutic targets for diabetic nephropathy by bioinformatics methods. Int J Mol Med. 2016;37:1181–1188. doi:10.3892/ijmm.2016.2527
   PubMedGoogle Scholar
• Pagel J, Deindl E. Disease progression mediated by Egr-1 Associated signaling in response to oxidative stress. Int J Mol Sci. 2012;13:13104–13117. doi:10.3390/ijms131013104
   PubMed Web of Science ®Google Scholar
• Zcharia E, Atzmon R, Nagler A, et al. Inhibition of matrix metalloproteinase-2 by halofuginone is mediated by the Egr1 transcription factor. Anticancer Drugs. 2012;23:1022–1031. doi:10.1097/CAD.0b013e328357d186
   PubMed Web of Science ®Google Scholar
• Wang D, Guan M, Zheng Z, et al. Transcription factor Egr1 is involved in high glucose-induced proliferation and fibrosis in rat glomerular mesangial cells. Cell Physiol Biochem. 2015;36:2093–2107. doi:10.1159/000430177
   PubMedGoogle Scholar
• Hu F, Xue M, Li Y, et al. Early Growth Response 1 (Egr1) Is a Transcriptional activator of NOX4 in oxidative stress of diabetic kidney disease. J Diabetes Res. 2018;2018:3405695. doi:10.1155/2018/3405695
   PubMedGoogle Scholar
• Xu P, Guan M, Bi J, Wang D, Zheng Z, Xue Y. High glucose down-regulates microRNA-181a-5p to increase pro-fibrotic gene expression by targeting early growth response factor 1 in HK-2 cells. Cell Signal. 2017;31:96–104. doi:10.1016/j.cellsig.2017.01.012
   PubMed Web of Science ®Google Scholar
• Li Y, Hu F, Xue M, et al. Klotho down-regulates Egr-1 by inhibiting TGF-β1/Smad3 signaling in high glucose treated human mesangial cells. Biochem Bioph Res Co. 2017;487:216–222. doi:10.1016/j.bbrc.2017.04.036
   PubMed Web of Science ®Google Scholar
• Ho L, Sung J, Shen Y, et al. Egr-1 deficiency protects from renal inflammation and fibrosis. J Mol Med. 2016;94:933–942. doi:10.1007/s00109-016-1403-6
   PubMed Web of Science ®Google Scholar
• Suda T. Hydrodynamic gene delivery its principles. Mol Ther. 2007. doi:10.1038/sj.mt.6300314
   PubMedGoogle Scholar
• Zhou L. Klotho ameliorates kidney injury and fibrosis and normalizes blood pressure by targeting the renin-angiotensin system. Am J Pathol. 2015;185:3211–3223. doi:10.1016/j.ajpath.2015.08.004
   PubMed Web of Science ®Google Scholar
• Saran R, Li Y, Robinson B, et al. US renal data system 2014 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2015;66:S1–S305. doi:10.1053/j.ajkd.2015.05.001
   PubMed Web of Science ®Google Scholar
• Hill CJ, Fogarty DG. Changing trends in end-stage renal disease due to diabetes in the United kingdom. J Ren Care. 2012;38:12–22. doi:10.1111/j.1755-6686.2012.00273.x
   PubMedGoogle Scholar
• Mizuiri S. ACE and ACE2 in kidney disease. World J Nephrol. 2015;4:74. doi:10.5527/wjn.v4.i1.74
   PubMedGoogle Scholar
• Cushman DW, Cheung HS. Concentrations of angiotensin-converting enzyme in tissues of the rat. Biochim Biophys Acta. 1971;250:261–265. doi:10.1016/0005-2744(71)90142-2
   PubMed Web of Science ®Google Scholar
• Dzau VJ, Bernstein K, Celermajer D, et al. Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovasc Drugs Ther. 2002;16:149–160. doi:10.1023/A:1015709617405
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, Li YC. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci U S A. 2008;105:15896–15901. doi:10.1073/pnas.0803751105
   PubMed Web of Science ®Google Scholar
• Zhou L, Li Y, Hao S, et al. Multiple genes of the renin-angiotensin system are novel targets of Wnt/beta-catenin signaling. J Am Soc Nephrol. 2015;26:107–120. doi:10.1681/ASN.2014010085
   PubMed Web of Science ®Google Scholar
• Pantzaris N, Karanikolas E, Tsiotsios K, Velissaris D. Renin Inhibition with Aliskiren: a decade of clinical experience. J Clin Med. 2017;6:61. doi:10.3390/jcm6060061
   PubMedGoogle Scholar
• Ortiz A, Bustos C, Alonso J, et al. Involvement of tumor necrosis factor-alpha in the pathogenesis of experimental and human glomerulonep hritis. Adv Nephrol Necker Hosp. 1995;24:53–77.
   PubMedGoogle Scholar
• Boyle JJ, Weissberg PL, Bennett MR. Tumor necrosis factor-alpha promotes macrophage-induced vascular smooth muscle cell apoptosis by direct and autocrine mechanisms. Arterioscler Thromb Vasc Biol. 2003;23:1553–1558. doi:10.1161/01.ATV.0000086961.44581.B7
   PubMed Web of Science ®Google Scholar
• McKenzie JA, Ridley AJ. Roles of Rho/ROCK and MLCK in TNF-alpha-induced changes in endothelial morphology and permeability. J Cell Physiol. 2007;213:221–228. doi:10.1002/jcp.21114
   PubMed Web of Science ®Google Scholar
• Radeke HH, Meier B, Topley N, Ge J F, Habermehl GG, Resch K. Interleukin 1-alpha and tumor necrosis factor-alpha induce oxygen radical production in mesangial cel ls. Kidney Int. 1990;37:767–775. doi:10.1038/ki.1990.44
   PubMed Web of Science ®Google Scholar
• Barutta F, Bruno G, Grimaldi S, Gruden G. Inflammation in diabetic nephropathy: moving toward clinical biomarkers and targets for treatment. Endocrine. 2015;48:730–742. doi:10.1007/s12020-014-0437-1
   PubMed Web of Science ®Google Scholar
• Jia Y, Zheng Z, Guan M, et al. Exendin-4 ameliorates high glucose-induced fibrosis by inhibiting the secretion of miR-192 from injured renal tubular epithelial cells. Exp Mol Med. 2018;50(5):1–13. doi:10.1038/s12276-018-0084-3
   PubMed Web of Science ®Google Scholar
• Aziz KM. Correlation of urine biomarkers: microalbuminuria and spot urine protein among diabetic patients. application of spot urine protein in diabetic kidney disease, nephropathy, proteinuria estimation, diagnosing and monitoring. Recent Pat Endocr Metab Immune Drug Discov. 2015;9:121–133. doi:10.2174/1872214809666150708111022
   PubMedGoogle Scholar